Forte Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Forte Biosciences, Inc. (formerly Tocagen Inc.) on July 17, 2020. The report addresses a change in the Company's independent registered public accounting firm following the completion of a business combination with Forte Subsidiary, Inc. on June 15, 2020.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and auditor changes rather than financial performance data.
Material Changes
- Dismissal of Auditor: The Audit Committee approved the dismissal of Ernst & Young LLP as the independent registered public accounting firm, effective July 17, 2020.
- Engagement of New Auditor: The Audit Committee approved the engagement of Mayer Hoffman McCann P.C. as the new independent registered public accounting firm for the year ending December 31, 2020.
- Audit History: Reports by Ernst & Young LLP for the years ended December 31, 2019 and 2018, did not contain adverse opinions, disclaimers, or qualifications. There were no disagreements or reportable events between the Company and Ernst & Young LLP during these periods.
- Consultation History: No consultations were made with Mayer Hoffman McCann P.C. regarding accounting principles or reportable events prior to their engagement.
Outlook, Risks, and Management Commentary
Management confirmed that the change in auditors was part of the post-merger integration process, as Mayer Hoffman McCann P.C. previously served as the independent auditors for Forte Subsidiary. Ernst & Young LLP has reviewed the statements in this filing and agreed with them, as evidenced by a letter dated July 21, 2020.
Key Facts for Investor Verification
- Verify the effective date of the auditor change (July 17, 2020) and the transition timeline for the 2020 fiscal year.
- Confirm that no undisclosed disagreements or reportable events existed with the former auditor, Ernst & Young LLP.
- Review the attached Exhibit 16.1 (Letter from Ernst & Young LLP) to validate their concurrence with the filing statements.
- Monitor future filings for the first financial statements audited by Mayer Hoffman McCann P.C.